Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infection
Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children
A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to once daily integrase inhibitor administered with darunavir/ritonavir…
- Trial name
- SMILE (NCT02383108)
- Testing
- DTG +DRV/r, SOC
- Where
- 31 sites in Argentina, France and 9 more
- Volunteers
- 318 people
- Sponsor
- PENTA Foundation
HIV Infections
Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein/GLA-SE HIV-1 vaccines (PDPHV-201401) as a prime-boost regimen or co-administered…
- Trial name
- NCT03409276
- Testing
- env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant
- Where
- 6 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection, Subtype b
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load
The ANRS 171 SYNACTHIV trial is a monocenter pilot open label phase I trial. This trial will evaluate new procedures in LRA administration in 3 successive cohorts.
- Trial name
- SYNACTHIV (NCT05230368)
- Testing
- Decitabine cycle 1, Romidepsin cycle 1, Decitabine cycle 2
- Where
- 4 sites in Belgium, France
- Volunteers
- 9 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Tambua Mapema Plus - to Discover HIV Infection Early and Prevent Onward Transmission
This study will assess the impact of an HIV-1 RNA testing intervention targeting adult patients aged 18-39 years who seek urgent care for symptoms at primary care facilities and meet specific risk criteria for acute HIV…
- Trial name
- TMP (NCT03508908)
- Testing
- HIV-1 RNA testing
- Where
- Kenya
- Volunteers
- 2,887 people
- Sponsor
- University of Oxford
HIV Infections
Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1
Research Hypothesis: Administration of BMS-663068, a prodrug for HIV attachment inhibitor BMS-626529, will result in a mean decrease of at least 1 log10 in HIV RNA at Day 9 following 8 days of therapy in at least one dosing…
- Trial name
- NCT01009814
- Testing
- BMS-663068, Ritonavir
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- ViiV Healthcare
HIV/AIDS, Tuberculosis, Pulmonary
INSTI's For The Management of HIV-associated TB
This study is being conducted to assess the antiretroviral activity of a fixed-drug, single tablet, combination of Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir alafenamide 25mg (Biktarvy®) dosed twice daily in HIV-1 infected…
- Trial name
- INSIGHT (NCT04734652)
- Testing
- Biktarvy®, TLD- fixed-drug combination single tablet
- Where
- South Africa
- Volunteers
- 122 people
- Sponsor
- Centre for the AIDS Programme of Research in South Africa
HIV I Infection, Cardiovascular Risk Factor
Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV
This research application will explore the impact of the Non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine in the setting of established Nucleoside reverse transcriptase inhibitors (NRTIs) backbone [Tenofovir…
- Conditions
- HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders
- Trial name
- NCT04820933
- Testing
- Doravirine 100 Mg
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Texas Southwestern Medical Center
HIV Infection, Monoclonal Antibody, Human
Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults
Background: VRC01 is a manmade antibody directed against the human immunodeficiency virus (HIV). Antibodies fight infection. Researchers eventually want to know if VRC01 helps prevent or treat HIV infection.
- Conditions
- HIV Infection, Monoclonal Antibody, Human, HIV Antibodies, VRC01 Monoclonal Antibody
- Trial name
- NCT01993706
- Testing
- VRC-HIVMAB060-00-AB
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
To determine the potential effects of 28 days of nevirapine treatment on the steady-state pharmacokinetics of nelfinavir and of stavudine (d4T), and to further evaluate the pharmacokinetics of nevirapine in combination with…
- Trial name
- NCT00002381
- Testing
- Nelfinavir mesylate, Nevirapine, Stavudine
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment
The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632.
- Trial name
- NCT00004584
- Testing
- Atazanavir, Ritonavir, Saquinavir
- Where
- 38 sites in United States, Canada and 3 more
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of cabotegravir in neonates exposed to human immunodeficiency virus (HIV)-1.
- Trial name
- CABNATE (NCT07275606)
- Testing
- Oral CAB, IM CAB LA
- Where
- South Africa
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV-1-infection
A Clinical Trial of STP0404 in Adults With HIV-1 Infection
The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living with Human Immunodeficiency Virus Type 1 (HIV-1) infection.
- Trial name
- NCT05869643
- Testing
- Low-dose STP0404 (Pirmitegravir), Medium-dose STP0404 (Pirmitegravir), High-dose STP0404 (Pirmitegravir)
- Where
- 13 sites in United States
- Volunteers
- 25 people
- Sponsor
- ST Pharm Co., Ltd.
HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued baseline antiretroviral therapy (ART), through Week 48; and to evaluate the…
- Trial name
- NCT05631093
- Testing
- ART, DOR/ISL
- Where
- 53 sites in United States, Australia and 6 more
- Volunteers
- 553 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, HIV Seronegativity
A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
PRIMARY: To determine the safety of envelope recombinant proteins rgp120/HIV-1MN (Genentech) and rgp120/HIV-1SF2 (Chiron/Biocine) in infants who are of indeterminate HIV status born to HIV-infected women.
- Trial name
- NCT00000774
- Testing
- rgp120/HIV-1MN, rgp120/HIV-1 SF-2
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparison of Two Tests for Anti-HIV Drug Resistance
The purpose of this study is to compare 2 different types of tests of the HIV virus to see which specific anti-HIV drugs would work the best. Drug resistance is a major reason for therapy failure in HIV patients.
- Trial name
- NCT00006490
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Helminthiasis
Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation
Identifying methods to slow disease progression in patients with HIV-1 infection remains a top priority in many regions of the world.
- Trial name
- NCT00130910
- Testing
- Albendazole
- Where
- Kenya
- Volunteers
- 234 people
- Sponsor
- University of Washington
HIV-1-infection
The Partners Scale-Up Project
An implementation project to scale-up delivery of antiretroviral-based HIV-1 prevention methods to Kenyan HIV-1 serodiscordant couples in HIV-1 care centers.
- Trial name
- NCT03052010
- Testing
- Integrated PrEP as a bridge to ART HIV-1 prevention strategy, PrEP, ART
- Where
- 2 sites in Kenya
- Volunteers
- 4,898 people, healthy volunteers welcome
- Sponsor
- University of Washington
Infection, Human Immunodeficiency Virus
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
GSK1349572 is an integrase inhibitor that will be evaluated for the treatment of HIV infection. This phase IIa, multicenter, randomized, parallel, double-blind, dose ranging, placebo-controlled 'proof of concept' study is to be…
- Trial name
- NCT00708110
- Testing
- GSK1349572
- Where
- 18 sites in United States
- Volunteers
- 35 people
- Sponsor
- ViiV Healthcare
HIV-1-infection
Second-line Switch to Dolutegravir Study
Kenya has the 4th largest HIV burden in the world with about 1.6 million people living with HIV. Of these, just over 1 million are on antiretroviral therapy (ART).
- Trial name
- 2SD (NCT04229290)
- Testing
- Dolutegravir
- Where
- 4 sites in Kenya
- Volunteers
- 795 people
- Sponsor
- University of Nairobi
HIV Infections
Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients
Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. Examine the ability of thymopentin to stimulate the immune system and alter the clinical findings of patients infected with…
- Trial name
- NCT00002049
- Testing
- Thymopentin
- Where
- United States
- Sponsor
- Immunobiology Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.